ATB 200

Drug Profile

ATB 200

Alternative Names: AT-B200/AT2220; ATB 200+chaperone; ATB-200; ATB200/AT2221; rhGAA-Amicus Therapeutics

Latest Information Update: 17 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amicus Therapeutics
  • Class Alpha-glucosidases; Enzymes
  • Mechanism of Action Alpha glucosidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glycogen storage disease type II
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Glycogen storage disease type II

Most Recent Events

  • 04 Oct 2017 Additional safety and efficacy data from a phase I/II trial in Glycogen storage disease type II released by Amicus Therapeutics
  • 21 Sep 2017 ATB 200 receives Orphan Drug status for Glycogen storage disease type II (Combination therapy) in USA
  • 15 May 2017 Adverse events, pharmacodynamic and efficacy data from a phase I/II trial in Glycogen storage disease type II (Combination therapy) released by Amicus Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top